UK Life Science Strategy Urges Continued Regulatory, Research Ties With EU
Executive Summary
Amid the continuing angst over Brexit, the UK’s new Life Science Industrial Strategy recommends continued close alignment of the UK and EU regulatory systems and says steps should be taken to ensure the UK can continue to attract the most talented scientists and researchers from Europe and from the rest of the world.
You may also be interested in...
Will ‘Transformative’ UK Life Sciences Sector Deal Help Offset The Brexit Effect?
The UK government has published its life sciences sector deal, which it says will allow the UK to respond to the challenges and opportunities of demographic change and pioneering research and development – although there is no mention of the “Brexit effect.”
UK Urged To Take Lead on Novel Clinical Trials, Foster Digital Tools
With Brexit looming, the UK life sciences industry has called on the government to do more to bolster the country’s ability to attract clinical trials, particularly those with novel designs. It has also proposed a “translational fund” to support the pre-commercial creation of “clinically-useable” products.
Regulatory Alignment Of UK With EU Post-Brexit Seen As Critical
Retain high-quality regulatory capability and the innovative leadership of the UK medicines agency, align with the EU and don’t build a stand-alone regulatory system. Those are some of the recommendations in the new and wide-ranging industry-led Life Sciences Industrial Strategy relating to the future, post-Brexit regulation of medicines in the UK.